Metabolic dysfunction-associated steatotic liver disease (MASLD), is closely linked to type 2 diabetes (T2D).1 2 This strong association is due to shared pathophysiological pathways, including insulin resistance, mitochondrial dysfunction, adipose tissue dysfunction, low-grade inflammation and dysbiosis.3 The coexistence of MASLD and T2D affects the prognosis of both diseases in a bidirectional manner that is not yet fully understood.3 Given this connection, the impact of glucose-lowering therapies on MASLD has been an important area of investigation. Among these therapies, sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been associated with a decrease in liver fat content, liver enzymes and histological feature of metabolic dysfunction associated steatohepatitis (MASH) beyond their well-established cardio–renal benefits. In a study published in Gut , Mao et al performed a retrospective analysis of 399 126 patients diagnosed with T2D and MASLD, using US healthcare claims data from 2007 to 2021.4 The study used propensity score matching to compare long-term outcomes in patients treated with SGLT2i (15.7%) versus those treated …

中文翻译：

---

MASLD 治疗 2 型糖尿病：个性化医疗的新证据


代谢功能障碍相关的脂肪性肝病 （MASLD） 与 2 型糖尿病 （T2D） 密切相关。1 2 这种强烈的关联是由于共同的病理生理途径，包括胰岛素抵抗、线粒体功能障碍、脂肪组织功能障碍、低度炎症和生态失调.3 MASLD 和 T2D 的共存以尚未完全了解的双向方式影响这两种疾病的预后.3 鉴于这种联系， 降糖疗法对 MASLD 的影响一直是一个重要的研究领域。在这些疗法中，钠-葡萄糖协同转运蛋白 2 抑制剂 （SGLT2i） 与肝脏脂肪含量、肝酶和代谢功能障碍相关脂肪性肝炎 （MASH） 的组织学特征降低有关，超出了其公认的心肾益处。在发表在《肠道》上的一项研究中，毛 等人使用 2007 年至 2021 年的美国医疗保健索赔数据，对 399 126 名被诊断患有 T2D 和 MASLD 的患者进行了回顾性分析。